Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same

US9078921B2 · kind B2 · utility

Assignee

• Abb Vie Deutschland Gmbh & Co. KG · DE

Inventors

• Jörg Rosenberg · Ellerstadt, DE
• Jorg Breitenbach · Mannheim, DE
• Kennan C. Marsh · Lake Forest, US
• Bernd Liepold · Dossenheim, DE
• Christoph Schmidt · Kriftel, DE
• Ute Lander · Dannenfels, DE

Key dates

• Filing date: Jul 17, 2007
• Grant date: Jul 14, 2015
• Expiry date: Nov 1, 2031

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K9/2027
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A pharmaceutically acceptable solubilizing composition comprising (i) at least one tocopheryl compound having a polyalkylene glycol moiety and (ii) at least one alkylene glycol fatty acid monoester or mixture of alkylene glycol fatty acid mono- and diester is disclosed. The solubilizing composition is useful in the manufacture of a pharmaceutical dosage form which comprises a melt-processed mixture of at least one active ingredient, at least one pharmaceutically acceptable polymer. The active ingredient(s) may be inhibitors of HIV protease. The solubilizing composition enhances the bioavailability of the active ingredient after oral intake.